San Francisco startup Framework Therapeutics can also be working on an oral, after-every day GLP-one drug called GSBR-1290—the drug surpassed Wall Road’s expectations in June when a mid-phase review confirmed ordinary weight loss of close to 6% and it designs to start out A different mid-phase trial toward the top of this yr—that founder and